EP
KYTX icon

Essential Partners’s Kyverna Therapeutics KYTX Stock Holding History

Essential Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-123
Closed -$378 – 2805
2025
Q2 		$378 Buy
+123
New +$304 ﹤0.01% 1773

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $926M AUM 11.38% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Essential Partners's KYTX Position: Q3 2025 in Review

Essential Partners sold out of Kyverna Therapeutics (KYTX) in Q3 2025, closing a stake of 123 shares — an estimated $378 sold.

Essential Partners first reported a position in KYTX in Q2 2025 and held it in 1 quarter. The position peaked at $378 in Q2 2025. 75 funds tracked by Wall St. Rank hold KYTX as of Q3 2025.

  • Essential Partners reported no remaining Kyverna Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 123 Kyverna Therapeutics shares in Q3 2025, an estimated $378.
  • Essential Partners first reported a position in Kyverna Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Kyverna Therapeutics position peaked at $378 in Q2 2025.
  • 75 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.